Tirzepatide pens contain a triple hormone receptor agonist that simultaneously activates GLP-1, GIP and glucagon receptors. This innovative mechanism makes tirzepatide pens particularly effective for metabolic research applications.
The active compound in tirzepatide pens has demonstrated significant effects in clinical studies, with weight reduction results comparable to bariatric surgery outcomes. Researchers have observed up to 24.2% body weight reduction in trial participants.
For diabetes research, tirzepatide pens show excellent glucose control properties, effectively lowering HbA1c levels. The multi-target action provides superior metabolic regulation compared to single-receptor agonists.
Our tirzepatide pens are supplied as lyophilized powder in sterile vials, ensuring maximum stability and convenient reconstitution for laboratory use. The product undergoes rigorous quality control testing to guarantee purity and consistency.
Proper storage is essential for maintaining peptide integrity. Tirzepatide pens should be stored at 2-8°C in their lyophilized form. For long-term preservation, we recommend storage at -20°C or below in sealed containers with desiccant.
This product is intended for research purposes only. Not for human consumption or diagnostic use. Researchers should follow all applicable laboratory safety protocols when handling tirzepatide pens.